Arkolith/Insider Trading/TBPH/Form 4/A

Broshy Eran

DirectorTheravance Biopharma, Inc. (TBPH) · full profile →Form 4/A · filed Nov 14, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$809K
Net Open-Market Flow
-$809K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 11, 2025Sell(S)14K$18.50$259K60K
Nov 11, 2025Sell(S)16K$18.50$287K76K
Nov 11, 2025Sell(S)16K$17.00$264K60K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 11, 2025Option exercise(M)14K$10.15$142K108K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0001256230-25-000007) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML